TABLE 1.
The cytotoxicity of ARS-1620 on ABCB1-overexpressing cancer cells.
| Cell lines | IC50 ± SD a (RF b ) (μM) | |||||
|---|---|---|---|---|---|---|
| Doxorubicin | Doxorubicin + verapamil 3 μM | Paclitaxel | Paclitaxel + verapamil 3 μM | ARS-1620 | ARS-1620 + verapamil 3 μM | |
| KB-3-1 | 0.023 ± 0.010 (1.00) | 0.030 ± 0.007 (1.31) | 0.006 ± 0.001 (1.00) | 0.005 ± 0.002 (0.83) | 9.300 ± 3.605 (1.00) | 11.001 ± 1.082 (1.18) |
| KB-C2 | 1.546 ± 0.047 (66.48) | 0.021 ± 0.004 (0.91)* | 2.961 ± 0.350 (534.10) | 0.126 ± 0.020 (22.70)* | 58.566 ± 2.363 (6.30) | 25.020 ± 3.971 (2.69)* |
| SW620 | 0.090 ± 0.020 (1.00) | 0.094 ± 0.006 (1.05) | 0.051 ± 0.004 (1.00) | 0.060 ± 0.013 (1.18) | 14.916 ± 1.120 (1.00) | 12.923 ± 1.737 (0.87) |
| SW620/Ad300 | 5.329 ± 0.092 (59.18) | 0.795 ± 0.139 (8.83)* | 3.522 ± 0.122 (69.01) | 0.342 ± 0.106 (6.69)* | 44.063 ± 3.695 (2.95) | 14.751 ± 1.652 (0.99)* |
| HEK293/pcDNA3.1 | 0.078 ± 0.011 (1.00) | 0.107 ± 0.044 (1.37) | 0.045 ± 0.008 (1.00) | 0.059 ± 0.009 (1.37) | 10.991 ± 1.700 (1.00) | 11.380 ± 2.485 (1.04) |
| HEK293/ABCB1 | 2.382 ± 0.703 (30.58) | 0.062 ± 0.009 (0.80)* | 1.610 ± 0.222 (35.65) | 0.057 ± 0.019 (1.26) * | 33.739 ± 7.157 (3.07) | 12.027 ± 3.322 (1.09)* |
a
IC50 values were represented as mean ± SD acquired from at least three independent experiments.
b
Resistance fold (RF) was calculated from dividing the IC50 values of parental or resistant cells in each treatment by the IC50 values of corresponding parental cells with doxorubicin, paclitaxel or ARS-1620, and without verapamil.
*p < 0.05 versus control treatment.